Alfasigma S.p.A. clinical trials

The registry lists 59 studies whose lead sponsor is Alfasigma S.p.A. or one of 3 companies grouped under it. 3 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 20, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 59. Browse all 59 →

• A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative ColitisRecruitingNCT06865417Phase 3
• OLE Study With Filgotinib in JIARecruitingNCT07553182Phase 3
• Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and AdolescentsRecruitingNCT07554495Phase 3
• STUDY OF THE EFFECTS OF L. CASEI DG® (ENTEROLACTIS BABY) IN HEALTHY PRETERM AND FULL-TERM INFANTS.CompletedNCT07882537Not applicable
• Filgotinib in Long-Term Extension Study of Adults With Ulcerative ColitisCompletedNCT02914535Phase 3
• Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid ArthritisCompletedNCT03025308Phase 3
• Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBCTerminatedNCT04594694Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBCCompletedNCT05239468Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)TerminatedNCT06222034Phase 1
• Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomyTerminatedNCT06121375Phase 2/3

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and BezafibrateTerminatedNCT06488911Phase 3

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted after Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in FranceCompletedNCT05323591
• FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) StudyTerminatedNCT05639543Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)Active, not recruitingNCT05817942
• A Study Evaluating the Effect of Filgotinib in Participants With Active Axial SpondyloarthritisActive, not recruitingNCT05785611Phase 3
• Prospective Observational Study of Filgotinib in Subjects With Rheumatoid ArthritisActive, not recruitingNCT04871919
• Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).CompletedNCT05724069Phase 2
• Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)CompletedNCT00391820Phase 2
• Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly SubjectsCompletedNCT01467726Phase 1
• Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC PatientsCompletedNCT05292872

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid TreatmentTerminatedNCT02548351Phase 3

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular RosaceaCompletedNCT05150587Phase 2
• Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)TerminatedNCT00550862Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompletedNCT03439254Phase 3

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC PatientsWithdrawnNCT05293938

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Obeticholic Acid in Pediatric Subjects With Biliary AtresiaTerminatedNCT05321524Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary CholangitisTerminatedNCT02308111Phase 4

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Study of Obeticholic Acid (OCA) Evaluating Pharmacokinetics and Safety in Participants With Primary Biliary Cholangitis (PBC) and Hepatic ImpairmentTerminatedNCT03633227Phase 4

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary CirrhosisCompletedNCT01865812Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.TerminatedNCT03469050Phase 2/3
• A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence PreventionTerminatedNCT03537157Phase 2
• Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)CompletedNCT02177136Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Study of INT-747 as Monotherapy in Participants With Primary Biliary Cirrhosis (PBC)CompletedNCT00570765Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary CirrhosisCompletedNCT01473524Phase 3

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• AvidinOX + [177Lu]DOTA-biotin (or 177Lu-ST2210) Complex in Patients With Liver Metastases From Colorectal CancerTerminatedNCT02053324Phase 1
• Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or LymphomasTerminatedNCT03188328Phase 1
• Safety and Efficacy of Rifaximin in Patients With Papulopustular Rosacea and Positive Lactulose Breath TestStatus unknownNCT03864978Phase 2
• A Trial to Evaluate the Efficacy and Safety of PMF104 Compared to a Conventional PEG-electrolyte Solution in ChildrenStatus unknownNCT03106922Phase 3
• Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax MalariaTerminatedNCT02110784Phase 2
• Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)CompletedNCT02633956Phase 2

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial VaginosisTerminatedNCT02376972Phase 2
• A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia PatientsCompletedNCT01091506Not applicable

  Sponsor listed in the registry: Pamlab, Inc. · Pamlab, Inc. — acquired company within the Alfasigma S.p.A. group

• The Nutritional Benefits of Metanx in Patients With Diabetic Peripheral Neuropathy (MEDIAN)Status unknownNCT01990092Not applicable

  Sponsor listed in the registry: Pamlab, Inc. · Pamlab, Inc. — acquired company within the Alfasigma S.p.A. group

• Effect of Cerefolin®/CerefolinNAC® on Biomarker MeasurementsCompletedNCT01745198

  Sponsor listed in the registry: Pamlab, Inc. · Pamlab, Inc. — acquired company within the Alfasigma S.p.A. group

• Effect of Food on Pharmacokinetics of Obeticholic Acid (OCA)CompletedNCT01914562Phase 1

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Deplin® P.L.U.S. Program (Progress Through Learning Understanding & Support)CompletedNCT01369030

  Sponsor listed in the registry: Pamlab, Inc. · Pamlab, Inc. — acquired company within the Alfasigma S.p.A. group

• A Retrospective Analysis of Cerefolin NAC® in Cognitively Impaired PatientsStatus unknownNCT01594541

  Sponsor listed in the registry: Pamlab, Inc. · Pamlab, Inc. — acquired company within the Alfasigma S.p.A. group

• Combination Deplin® and Antidepressant Therapy for a Major Depressive Episode (MDE)- a Retrospective AnalysisCompletedNCT01001559

  Sponsor listed in the registry: Pamlab, Inc. · Pamlab, Inc. — acquired company within the Alfasigma S.p.A. group

• Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)CompletedNCT01933503Phase 1

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.

• Hepatic Impairment Trial of Obeticholic AcidCompletedNCT01904539Phase 1

  Sponsor listed in the registry: Intercept Pharmaceuticals · First submitted before Intercept Pharmaceuticals became part of Alfasigma S.p.A.